A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Public ClinicalTrials.gov record NCT06040099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Study identification
- NCT ID
- NCT06040099
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Drug
- Bevacizumab Drug
- Transarterial Radioembolization (TARE) Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2024
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
- Last update posted
- Mar 18, 2026
2024 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Gainesville | Florida | 32608 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Boston | Massachusetts | 02118 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Trenton | New Jersey | 08690 | — |
| Research Site | Buffalo | New York | 14263 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Charlottesville | Virginia | 22908 | — |
| Research Site | Seattle | Washington | 98195 | — |
| Research Site | Milwaukee | Wisconsin | 53215 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06040099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2026 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06040099 live on ClinicalTrials.gov.